Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.
Source: European Heart Journal - Category: Cardiology Source Type: research